+34 679 490 537info@nanbiosis.com

Nanbiosis

U1. Protein Production Platform Unit (PPP)

Ciber bbn

U1. Protein Production Platform (PPP)

U1. PPP logo IBB UAB
Order request

Description

The PPP Unit is at the Institute of Biotechnology and biomedicine of the Autonomous University of Barcelona (IBB-UAB) and counts with the necessary facilities for the design, production and purification of recombinant proteins. This facility is coordinated by the Nanobiotechnology Group, leaded by Prof. Antonio Villaverde. It has both highly specialized personnel and the necessary equipment to offer an “tailored” service for the design, production and purification of recombinant proteins using both prokaryotic and eukaryotic expression systems. Its location allows this service to be linked with other complementary services available within the university (Cell Culture, Cytometry, Production of Antibodies, Microscopy, Proteomic, and Bioinformatic,X-ray crystallography, and the Microarray and Sequencing Services), as well as facilitating the management of subsequent uses of the produced protein.

Counts with a laboratory perfectly equipped for the bioproduction of proteins, other with all the necessary equipment for the molecular cloning, plus one lab for the purification and characterization, and finally one for cryopreservation.

The PPP Unit is also applying for the ISO9001 certification forstandard quality control system.

News U1

02 Mar

U1 NANBIOSIS - Public-Private collaboration to Investigate New Inhibitors Against Pain
Public-Private collaboration to Investigate New Inhibitors Against Pain

Unit 1 of NANBIOSIS, together with Synchroton Alba and the pharmaceutical ESTEVE jointly investigate the mechanisms of new inhibitors against pain ESTEVE, a chemical – pharmaceutical group leader in Spain and with an important international presence, has developed new inhibitors against pain. Collaboration with scientific expertise of the Protein Production Platform and the ALBA Synchrotron will allow studyingthe interaction of these inhibitors with its potential target. The results of the research may help to the better understanding of the effects of the inhibitors and will provide key information to improve their properties. The  Protein Production Platform (Unit 1 of NANBIOSIS) is in[...]

28 Jun

“a-Galactosidase A Loaded Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration”
“a-Galactosidase A Loaded Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration”

Unit 1 of NANBIOSIS, Protein Production Platform (PPP), Unit 3, Synthesis of Peptides, Unit 20, In Vivo Experimental Platform and Unit 6, Biomaterial Processing and Nanostructuring Unit, have jointly developed the research conducted in relation with a CO2-based methodology for the one-step production of protein-nanoliposome conjugates as bio-active nanomaterials with therapeutic interest. The results have been published in Advanced Healthcare Materials: http://www.ncbi.nlm.nih.gov/pubmed/26890358 “a-Galactosidase A Loaded Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration I. Cabrera, I. Abasolo, J. L. Corchero, E. Elizondo,  P. Rivera, E. Moreno, J. Faraudo, S. Sala, D. Bueno, E. González-Mira, M. Rivas, M. Melgarejo, D. Pulido,[...]

18 Apr

Nanbiosis_Unit 1 of NANBIOSIS certified with ISO 9001- 2008
Unit 1 of NANBIOSIS certified with ISO 9001: 2008

Unit 1 of NANBIOSIS, Production Platform Protein (PPP) at the Autonomous University of Barcelona, ​​directed by Dra. Neus Ferrer and coordinated by Professor Antonio Villaverde, provides the service of production and purification of recombinant proteins in different systems expression, microbial and non-microbial. This service was audited last November, based on the UNE EN ISO 9001: 2008 AENOR, who has issued a favourable certification report. The requirements of this standard cover all aspects of management. This certification will expand and consolidate the service  that the Unit 1 of NANBIOSIS is giving to companies and public sector researchers and facilitate their integration[...]

31 Mar

Nanbiosis Ibb news
MEMBERS OF THE IBB WILL INVESTIGATE THE EARLY DIAGNOSIS OF PARKINSON

Researchers from the Folding and Conformational Diseases Group at the Institute of Biotechnology and Biomedicine Group are part of the European project Neuromed to develop molecules and detect biomarkers of this disease before the signs of neurodegeneration become evident. The Neuromed project is led by the University of Zaragoza and aims to design molecules, drugs and new diagnostic tools early for three neurodegenerative diseases in which defective proteins are involved: Parkinson’s disease and two rare diseases, phenylketonuria and protein TTR Amyloidosis. The coordination of the Parkinson’s research line will be directed, from the IBB, by Salvador Ventura, principal researcher and[...]

U1-Protein Production Platform - PPP
Read More

U6. Biomaterial Processing and Nanostructuring Unit

Ciber bbn

U6. Biomaterial Processing and Nanostructuring Unit

  • Scientific Coordinator: Dr. Santi Sala sala@icmab.es
  • Entities: Instituto de Ciencia de Materiales de Barcelona ICMAB-CSIC
  • Address: Campus de UAB, 08193, Bellaterra, Barcelona, Spain
  • Phone: +34 935 801 853
  • Fax: +34 935 805 729
  • Web: ICMAB
ICMAB CSIC
Order request

Description

Located at the Instituto de Ciencia de Materiales de Barcelona (ICMAB-CSIC), in Barcelona, and under the coordination of Professor Jaume Veciana, current director of NANOMOL Group, gathers several laboratories to perform the mission of this facility: the characterization, development and large-scale production ofmolecular biomaterials of therapeutic or biomedical interest, with controlled micro-, nano- and supramolecular structure.
This unit is composed of the equipment and the scientific and technical personnel to develop and apply efficient, robust and green technologies based on the use of supercritical fluids (or dense gases), such as compressed CO2. The main activity of this unit is focused on the production of pure micro- and nanoparticulate active therapeutic ingredients and passive or active therapeutic nanoconjugates (vesicles, liposomes, nanosuspensions, micro- and nanostructured polymeric particles), as well as porous matrices of biocompatible polymers for tissue engineering or implants. The unit has also instruments and the necessary know-how to undertake nanostructuring of molecular biomaterials in films and surfaces, with application in the development of new biomedical devices. The facilities are equipped with laboratory and pre-pilot scale plants, high pressure phase analyzers and analytical instrumentation for micro- and nanoparticle physico-chemical characterization (particle size distribution, particle concentration, particle morphology and stability, Z-potential). One of the singularities of this unit is that counts with plants at different scales, from mL to L, which allow process development by QbD and process scale-up.
 
U6. Services & Rates

News U6

27 Jul

Nanomedicine applied to Dermatology by Almirall, Leitat Technology Center & NANOMOL (NANBIOSIS U6)

NANOMOL (ICMAB-CSIC), a research group member of ICTS “NANBIOSIS”, more specifically of the Biomaterial Processing and Nanostructuring Unit (U6), announced today the launch of Nano4Derm, a research project in collaboration with Almirall, S.A and Leitat Technology Center, focused in nanomedicine applied to treat dermatological diseases. Within the framework of this research project, new innovative formulations containing nanoencapsulated active ingredients will be developed for the topical treatment of inflammatory skin conditions, such as Acne and Psoriasis. Nano4Derm involves the development and physico-chemical and biological characterisation of nanocapsules containing active ingredients, and the generation of scalable formulation prototypes for manufacturing nanoformulations suitab[...]

13 Jul

Conflicting evidence for ferroelectricity – New publication in NATURE by scientists of NANBIOSIS

Researchers from Unit 6 of NANBIOSIS, -ICMAB (CSIC)/CIBER-BBN-, in collaboration with others from the Universities of Liège, Mons, Grenoble-Alpes, Parma, Augusburg, Girona and CNR-IOA (SISSA) have published in the journal Nature (G. D’Avino et al., Nature, 547, E9-E10, 2017) an article questioning the presence of ferroelectricity at room temperature in organic charge transfer crystals, generated by supramolecular techniques, previously published in the same journal (Tayi et al, Nature, 488, 485-489, 2012), by a team led by Profs. J. Fraser Stoddart (Nobel Prize for Chemistry 2016) and Samuel I. Stupp of the University of Northwestern. For more information: D’Avino et al,[...]

16 May

Unit 6 of NANBIOSIS-ICTS Biomaterials processing and Nanostructuring at ICMAB-CSIC received the visit of high school students

A group of 22 students from the high school La Serra (Mollerusa) visited the Biomaterials and Nanostructuring Unit of NANBIOSIS,  at the Institute of Material Science of Barcelona of CSIC. The visit was an activity within the Nanoscience and Nanotechnology festival 10alamenos9  in which ICMAB participates. The students were guided through the labs by Amable Bernabé, technical responsible of U6, who explained them about nanotechnology, NANBIOSIS-ICTS research infrastructure and the different techniques available at “Biomaterials processing and Nanostructuring Unit”.[...]

15 May

NMR signal enhancement of >50 000 times in fast dissolution dynamic nuclear polarization

Jaume Veciana, Scientific Director of NANBIOSIS-ICTS has participated  in the research results published in the journal Chemical Communication, wich reports the synthesis and the study of a novel mixed biradical with BDPA and TEMPO radical units that are covalently bound by an ester group (BDPAesterTEMPO) as a polarizing agent for fast dissolution DNP. The biradical exhibits an extremely high DNP NMR enhancement of >50000 times, which constitutes one of the largest signal enhancements observed so far, to the best of our knowledge. Some of the researchs were made taking advantage of the characterization facilities provided by ICTS NANBIOSIS. For more information: L. F.[...]

11 May

NANOMOL group, coorditator of Unit 6 of NANBIOSIS has authored 26% of the scientific articles of ICMAB in NATURE

The Nature Index takes into account the published scientific articles from 1 February 2016 to 31 January 2017.  This index is elaborated annually based on the affiliations of the authors of scientific articles published in a selection of 68 high-quality journals (http://www.natureindex.com/faq#journals) CSIC appears as the first Spanish research centre in this ranking and occupies position number 38 in the global ranking of 500 research centres worldwide, while ICMAB occupies the first position within the CSIC centre, taking into account the corrected index WFC that shares the work between the different co-authoring institutions and corrects for the overrepresentation of som[...]

23 Apr

NANBIOSIS Scientific Director Dr. Jaume Veciana received a Mention of Honor for his dedication to NANBIOSIS

On April 22, Dr. Jaume Veciana received a Mention of Honor from the current President of Extremadura, Guillermo Fernández Vara, during the celebration of the X Anniversary of the Center for Minimally Invasive Surgery “Jesus Usón” for his commitment, effort and dedication in the creation of the Singular Scientific Technological Infrastructures (ICTS) NANBIOSIS, in collaboration with the Center for Biomedical Research Center in Bioingeneering, Biomaterials and Nanomedicine (CIBER-BBN). Further information:[...]

06 Apr

MATBIO 2017
Materials for Biomedical Applications Scientific School (BIOMAT-2017)

Registration is now open for the Scientific School on Materials for Biomedical Applications (BIOMAT-2017) that will take place on 19th-22nd of June 2017 in the UAB Campus (Barcelona). This school is organized by ICMAB-CSIC and it is included in the Severo Ochoa activities of the Institute. The school is addressed to last year undergraduate, master and PhD students, who are interested in the development of materials for biomedical applications. The aim of the school is to present the design, development and application of new materials for a wide range of biomedical applications. The school includes lectures from international and loca[...]

21 Dec

Validation of a drug for foot ulcers in collaboration with Cuba
Validation of a drug for foot ulcers in collaboration with Cuba

Nanomol, (Unit 6 of NANBIOSIS) has announced in Cuba that the process of clinical validation of a new drug developed and patented in collaboration with Center of Genetic Engineering and Biotechnology of Cuba, integrated in BioCubaFarma, has been initiated. The new drug is designed to improve the healing of foot ulcer in diabetics and could be on the market in five years. The collaboration of the Center for Genetic Engineering and Biotechnology of Cuba with Nanomol, coordinating group of Unit 6 of NANBIOSIS, began in 2010. Cuban researchers had developed an effective product in wound healing in diabetics but t[...]

U6-Biomaterial Processing and Nanostructuring Unit
Read More

U10. Drug Formulation

Ciber bbn

U10. Drug Formulation

  • Scientific Director: Prof. José Luis Pedraz joseluis.pedraz@ehu.es
  • Scientific Coordinator: Dr. Jesús Ciriza Astrain jeciriza@gmail.com
  • Entities: Universidad del País Vasco (UPV/EHU)
  • Address: Pharmacy & Pharmac. Technology Lab.; Facultad de Farmacia, C/Paseo de la Universidad 7, 01006 Vitoria-Gasteiz (Spain)
  • Phone: +34 945 013091
  • Fax: +34 945 013040
  • Web: NANOBIOCEL UPV/EHU
UPV-EHU
Order request

Description

Located at the Faculty of Pharmacy, University of the Basque Country (UPV), Campus of Vitoria, is led by Prof. José Luis Pedraz and consists of large laboratories for: cell culture, chromatography equipment, sample preparation and characterization and one specific for scale preparation of pharmaceutical formulations. This Unit has the capacity to design and evaluate dosage forms both classical and new dosage forms of biotech drugs, DNA, RNA and vaccines using different methodologies based on micro and nano-medicine. The latter methodology based on the microencapsulation of cells, peptides, proteins, and in general of biotech products, as well as the development and design of non-viral vectors for gene therapy, is one of the biggest singularities of this unit. It counts with the most advanced equipment for micro and nano encapsulation.

The aim of the Unit is to determine experimentally all the variables needed to develop an optimal formulation and work instructions for preparing final pharmaceutical products.

The pharmaceutical technology applied to drug development involves the selection of materials and procedures that can be adapted to different processes that lead to specific pharmaceutical forms. To do that, the Unit counts with the most advanced equipment to cover the development for all the steps of the process.

One of the singularities of this Units is that is GLP certified by the Spanish Medicament Agency

News U10

16 May

New gelatine devices that mimic the body’s activity in bone regeneration

The NanoBioCel Group, Coordinator of Unit 10 of NANBIOSIS has led the development of new scaffolds (such as burns, trauma or tumour extractions), to regenerate critical bone defects that, in addition to physical support, offers the opportunity to release growth factors temporarily replacing the bone matrix and aiding the regeneration of bone tissue. In order [...]

18 Apr

New treatments for degenerative diseases of the retina

The final meeting of the TERET project took place last March, an initiative within the RETOS public-private collaboration initiative of the Ministry of Economy, Industry and Competitiveness funded with almost € 1 million. The project has been carried out over the past three years to develop new treatments for degenerative diseases of the retina, focusing [...]

09 Feb

bioprinted human cells
3DBio-impression systems and bio-ink for the regeneration of cartilage and bone

The Nanobiocel Group, coordinator of Unit 10 of NANBIOSIS participate in a public-private collaborative project to reach clinical application in the regeneration of osteochondral lesions, which mainly affect the knee and ankle joints. The new project is funded by the Challenges-Collaboration program of the Ministry of Economy, Industry and Competitiveness. It has a budget of [...]

18 Jan

Nanomedicine in B·Debate Fighting Blindness by Unit 10 of NANBIOSIS
Nanomedicine in B·Debate Fighting Blindness by Unit 10 of NANBIOSIS

The recent published Newsletter of Institut of Màcula and the Barcelona Màcula Foundation: Research for Vision reported about the forum  B·Debate Fighting Blindness. Future Challenges and Opportunities for Visual Restoration, September 6-7 , that gathered more than thirty experts in the different areas related with blindness. The second Session, about Nanotechnology and Nanomedicine, was chaired [...]

13 Jan

Nanbiosis U10 Micro and nano capsules that will increase the effectiveness and precision of medicine.
Micro and nano capsules that will increase the effectiveness and precision of medicine.

José Luis Pedraz, Scientific Director of Unit 10 of NANBIOSIS and members of NANOBIOCEL group, which coordinates Unit 10 of NANBIOSIS, explain for the TEKNOPOLIS program of EiTB, the first communication group in the Basque Country, the development of micro and nanocapsules, gels and scaffolds to solve the problems of administration of new drugs. The [...]

02 Dec

"It is necessary to increase our relationship with European research groups" by José Luis Pedraz - U10 of NANBIOSIS
“It is necessary to increase our relationship with European research groups” by José Luis Pedraz – U10 of NANBIOSIS

Last Sunday, November 27, the Newspaper of Álava published a special supplement with the title “ALAVA 2020”. It contained an article by José Luis Pedraz (Scientific Director of Unit 10 of NANBIOSIS) According to Dr. Pedraz, group leader of the CIBER-BBN NANOBIOCEL group, in the next future, important challenges with new technologies will allow a [...]

04 Oct

Midyear meeting in Vitoria of European project DRIVE
Midyear meeting in Vitoria of European project DRIVE

CIBER-BBN participates in the project through NanoBioCel group, led by professor José Luis Pedraz Muñoz, Scientific Director of Unit 10 of NANBIOSIS, working on the optimization of formulations to be included in a bioartificial organ. José Luis Pedraz Munoz and Jesus Izco coordinator of NANBIOSIS have participated in the meeting held in Vitoria on 3 [...]

03 Jun

Jesus Izco, Coordinator of NANBIOSIS and José Luis Pedraz, Scientific Director of Unit 10-Drug Formulation of NANBIOSIS and NanoBioCel Group of CIBER-BBN, participated in the 2ª General Assambly of DRIVE project, held in Venice, May 16th-17th 2016.
Nanbiosis in the 2ª General Assambly of DRIVE project, Venice (16th-17th 2016)

Jesus Izco, Coordinator of NANBIOSIS and José Luis Pedraz, Scientific Director of Unit 10-Drug Formulation  of NANBIOSIS and NanoBioCel Group of CIBER-BBN, participated in the 2ª General Assambly of  DRIVE project, held in Venice, May 16th-17th 2016. The second General Assembly of European project DRIVE “DIABETES-REVERSING-IMPLANTS FOR ENHANCED VIABILITY AND LONG TERM EFFICACY”, took place [...]

26 Apr

Nanbiosis_U10_Cationic nioplexes in supramolecular hydrogels as hybrid materials to deliver nucleic acids
Cationic nioplexes in supramolecular hydrogels as hybrid materials to deliver nucleic acids

Jose Luis Pedraz, Scientific Director of Unit 10 of NANBIOSIS and Ramon Eritja (CIBER-BBN) have participated in the entrapment of cationic nioplexes in supramolecular hydrogels and the use of these materials for transfecting cells. This work is focused on entrapping cationic nioplexes within supramolecular hydrogels based on N-protected phenylalanine. To modulate the supramolecular hydrogel diffusion [...]

03 Mar

Nanbiosis_Unit8-Drive Project-Improving transplant pancreatic cells_Dr. Jose Luis Pedraz
Drive Project: Improving transplant pancreatic cells

José Luis Pedraz, Scientific Director of the Unit 10: Drug Formulation of NANBIOSIS explained DRIVE European project in the third edition of Diabetes Experience Day, diabetic patients meeting that gathered 1500 people in Madrid. The DRIVE project, in which participate fourteen partners from seven European countries, among which is the CIBER-BBN, develops biomaterials and new surgical devices to improve transplantation and survival of insulin-producing pancreatic islet for the treatment diabetes.

[...]

U10-Drug Formulation
Read More
Nanbiosis